Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus

NCT ID: NCT00772980

Last Updated: 2010-07-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subjective Tinnitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Drug: Neramexa mesylate Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day

Group Type EXPERIMENTAL

Neramexane mesylate

Intervention Type DRUG

Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.

2

Drug: Placebo Double-blind treatment period of 17 weeks placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neramexane mesylate

Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.

Intervention Type DRUG

Placebo

Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients aged 18 to 75 years with a clinical diagnosis of first onset, persistent (i.e. tinnitus sghould never be absent for \>24 hours in a row), subjective, uni-or bilateral tinntius present for at least 3 months but not more than 12 months.

Exclusion Criteria

* Clinical diagnosis of intermittent or pulsatile tinnitus
* Patients who have tinnitus as a concomitant symptom of an otological/neurological disease(such as otitis media, Meniére´s disease, otosclerosis, etc.)
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merz Pharmaceuticals GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Merz Pharmaceuticals GmbH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AZ Sint Lucas, ENT department

Assebroek-Brugge, , Belgium

Site Status

University Hospital Brussels, ENT department

Brussels, , Belgium

Site Status

Clinique Universitaire Saint-Luc

Brussels, , Belgium

Site Status

Dr. Henri HABERMAN

Brussels, , Belgium

Site Status

AZ Sint Lucas, ENT department

Ghent, , Belgium

Site Status

Centre hospitalier de jolimont

La Louvière, , Belgium

Site Status

University Hospital Leuven, ENT Department

Leuven, , Belgium

Site Status

CHU Liege Service ORL

Liège, , Belgium

Site Status

Medico

Chodov, Prague, Czechia

Site Status

Prof. MUDr. Ivo Šlapák, CSc

Brno, , Czechia

Site Status

Teaching University Hospital, ORL klinika

Brno, , Czechia

Site Status

Nemocnice Havlíčkův Brod

Havlíčkův Brod, , Czechia

Site Status

ORL - Otorynolaryngologické oddělení

Jihlava, , Czechia

Site Status

ORL oddělení, Karlovarská krajská nemocncie a.s.

Karlovy Vary, , Czechia

Site Status

Oblastní nemocnice Kladno a.s.

Kladno, , Czechia

Site Status

Pro-audio,s.r.o.-private ENT clinic

Mladá Boleslav, , Czechia

Site Status

ORL oddělení, Všeobecná Fakultní Nemocnice v Praze

Prague, , Czechia

Site Status

ORL oddělení , Karlovarská krajská nemocnice a. s.

Sokolov, , Czechia

Site Status

Dr. Ebbo

Issy-les-Moulineaux, , France

Site Status

Dr. Sarfati

La Seyne-sur-Mer, , France

Site Status

Centre Hospitalier de Bretagne Sud Service

Lorient, , France

Site Status

Hopital Edouard Herriot

Lyon, , France

Site Status

BONFILS

Paris, , France

Site Status

OHRESSER

Paris, , France

Site Status

Hopital Nord

Saint-Etienne, , France

Site Status

FRAYSSE

Toulouse, , France

Site Status

Service ORL CHU

Tours, , France

Site Status

Hopital Paul BROUSSE Polyclinique

Villejuif, , France

Site Status

Andromed Breda

Breda, , Netherlands

Site Status

Andromed Leiden

Leiderdorp, , Netherlands

Site Status

Rijnland Ziekenhuis, ENT department

Leiderdorp, , Netherlands

Site Status

Adromed Nijmegen

Nijmegen, , Netherlands

Site Status

Andromed Rotterdam

Rotterdam, , Netherlands

Site Status

Andromed Rotterdam

Rotterdam, , Netherlands

Site Status

Andromed Oost

Velp, , Netherlands

Site Status

Andromed Zoetermeer

Zoetermeer, , Netherlands

Site Status

Uniwersytecki Szpital Kliniczny w Bialymstoku

Bialystok, , Poland

Site Status

Niepubliczny Zaklad Opieki Zdrowotnej Prywatne Centrum Medyczne PROMEDIS

Gdansk, , Poland

Site Status

Szpital Miejski im. J.Brudzinskiego

Gdynia, , Poland

Site Status

Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mieleckiego Slaskiego Uniwersytetu Medycznego w Katowicach

Katowice, , Poland

Site Status

NZOZ Specjalistyczne Centrum Medyczne Nowomed

Krakow, , Poland

Site Status

Specjalistyczny Gabinet Otolaryngologiczny Dr Anna Otto- Markiewicz

Krakow, , Poland

Site Status

Niepubliczny Zaklad Opieki Zdrowotnej PROMED

Krakow, , Poland

Site Status

Szpital Specjalistyczny im. Stefana Zeromskiego, SP ZOZ w Krakowie, Oddzial Otolaryngologii

Krakow, , Poland

Site Status

Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi

Lodz, , Poland

Site Status

Instytut Medycyny Pracy im. Prof. Dr med. Jerzego Nofera w Lodzi

Lodz, , Poland

Site Status

Wojewodzki Szpital Specjalistyczny im. Stefana Kardynała Wyszynskiego Samodzielny Publiczny Zaklad Opieki Zdrowotnej

Lublin, , Poland

Site Status

Wojewodzki Szpital Specjalistyczny w Olsztynie

Olsztyn, , Poland

Site Status

Instytut Fizjologii i Patologii Sluchu

Warsaw, , Poland

Site Status

Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu

Wroclaw, , Poland

Site Status

Louis Leipoldt Mediclinic

Bellville, , South Africa

Site Status

Lakeview Hospital

Benoni, , South Africa

Site Status

Dr. A. Viljoen

Pretoria, , South Africa

Site Status

GCT Eastmed Clinical Trial centre

Pretoria, , South Africa

Site Status

Constantiaberg Medi Clinic

Western Cape, , South Africa

Site Status

Dr. J. Steer

Wynberg, , South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Czechia France Netherlands Poland South Africa

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EudraCT Number 2008-000639-16

Identifier Type: -

Identifier Source: secondary_id

MRZ 92579/TI/3002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TNF-α Treatment of Blast-Induced Tinnitus
NCT04066348 RECRUITING PHASE2
OTO-313 in Subjects With Subjective Tinnitus
NCT03918109 COMPLETED PHASE1/PHASE2